HC Wainwright & Co. Downgrades HeartBeam to Neutral
HC Wainwright & Co. analyst Yi Chen downgrades HeartBeam (NASDAQ:BEAT) from Buy to Neutral.
Stocks · News reference
HeartBeam Wins U.S. Patent Expanding ECG Device With Acoustic Sensing, Impedance Features For Heart Disease Monitoring
Patent extends HeartBeam's ECG hardware platform with multi-modal sensing capabilitiesAcoustic sensors enable HeartBeam’s device to function as a "digital stethoscope" to assess heart valve functionThoracic
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
HeartBeam Enters ATM Equity Offering Agreement To Sell Up To $25M Of Common Stock Through Titan Partners Securities
On August 14, 2026, HeartBeam, Inc. (the "Company"), entered into an At-The-Market Equity Offering Sales Agreement (the "Sales Agreement") with Titan Partners Securities LLC, as sales agent, pursuant to
Heartbeam shares are trading lower after the company reported worse-than-expected Q2 EPS results.
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers MDxHealth (NASDAQ:MDXH) stock moved upwards by 120.8% to $1.02 during Friday's regular session. The company's market cap stands at $23.7 million. The company's, Q2 earnings came out yesterday.